Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington. Show more

Location: 22722 29th Dr. SE, Bothell, WA, 98021, United States | Website: https://www.achievelifesciences.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

146.2M

52 Wk Range

$1.84 - $5.31

Previous Close

$2.86

Open

$2.79

Volume

1,034,773

Day Range

$2.74 - $2.88

Enterprise Value

100.5M

Cash

55.4M

Avg Qtr Burn

-9.93M

Insider Ownership

3.55%

Institutional Own.

61.41%

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Cytisinicline Details Smoking cessation Suspected Mover™ Susp. Mover™	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cytisinicline Details Smoking cessation	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.